Latest news and press releases about Adaptimmune Therapeutics plc (ADAP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets.
Price
| Price | $0.05 |
| Market Cap | $75M |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | -0.18 |
| EV / EBITDA | -1.42 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 143.79% |
| Return on Invested Capital | -90.90% |
| Return on Assets | -59.65% |
| Gross Margin | 83.88% |
| Operating Margin | -362.66% |
| Net Margin | -371.74% |
Related companies: ANL · APLM · BLRX · ERNA · GOVX · LNAI · LPCN
Explore sector: Healthcare · Biotechnology
More sections of ADAP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks